Expand PRAX Menu
PRAX MENU

PRAX Latest Press Releases

-- March 30, 2026 --

Praxis Precision Medicines Announces FDA Acceptance and Priority Review of New Drug Application for Relutrigine in Patients with SCN2A and SCN8A DEEs Globe Newswire 4:01 PM

-- March 4, 2026 --

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:01 PM

-- February 19, 2026 --

Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results Globe Newswire 7:30 AM

-- February 9, 2026 --

Praxis Precision Medicines to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 19, 2026, and Participate in Upcoming Investor Conferences Globe Newswire 4:01 PM

-- February 4, 2026 --

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:01 PM

-- January 13, 2026 --

Praxis Precision Medicines Appoints Global Epilepsy Leader Dr. Orrin Devinsky as Head of Clinical Strategy Globe Newswire 4:30 PM

-- January 12, 2026 --

Praxis Precision Medicines Enters Its Next Chapter Following a Pivotal Year of Progress Globe Newswire 8:00 AM

-- January 9, 2026 --

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:01 PM

-- January 8, 2026 --

Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments Globe Newswire 4:45 PM

-- January 6, 2026 --

Praxis Precision Medicines, Inc. Announces Pricing of $575 Million Public Offering Globe Newswire 11:15 PM
Praxis Precision Medicines, Inc. Announces Proposed Public Offering Globe Newswire 4:03 PM

-- December 29, 2025 --

Praxis Precision Medicines Announces the FDA Has Granted Breakthrough Therapy Designation for Ulixacaltamide HCl in Essential Tremor Globe Newswire 8:00 AM

-- December 11, 2025 --

Praxis Precision Medicines Announces Plans to File an NDA for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies in Early 2026 Globe Newswire 8:00 AM

-- December 9, 2025 --

Praxis Precision Medicines Announces Alignment with FDA on Simplified and Accelerated Registrational Pathway for Elsunersen in Early Onset SCN2A Developmental and Epileptic Encephalopathy Globe Newswire 4:01 PM

-- December 8, 2025 --

Praxis AES Wrap-up: Best-in-Class Potential Across Rare Pediatric and Adult Epilepsies Globe Newswire 8:00 AM

-- December 4, 2025 --

Praxis Precision Medicines Announces Positive Results from EMBOLD Study for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies Globe Newswire 4:10 PM
Praxis Precision Medicines Announces Positive Pre-NDA Meeting with FDA for Ulixacaltamide in Essential Tremor Globe Newswire 4:01 PM

-- December 3, 2025 --

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:01 PM

-- November 24, 2025 --

Praxis to present latest preclinical and clinical advancements across leading epilepsy portfolio at the 2025 American Epilepsy Society (AES) Annual Meeting Globe Newswire 4:01 PM

-- November 20, 2025 --

Praxis Precision Medicines to Participate in Upcoming Fireside Chat Globe Newswire 4:01 PM

-- November 5, 2025 --

Praxis Precision Medicines to Participate in Upcoming Investor Conferences Globe Newswire 4:01 PM
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2025 Financial Results Globe Newswire 8:00 AM

-- November 4, 2025 --

Praxis announces accelerated development path for relutrigine in SCN2A and SCN8A DEE patients following positive FDA feedback Globe Newswire 8:00 AM
Market Data Delayed 15 Minutes